The company has not filed an annual or quarterly report since its Q1 FY2018 10-Q, filed May 15, 2018. Its latest SEC filing is a 3 from Sep 12, 2018.
10-Q for Q1 FY2018, filed May 15, 2018
The sections below describe the company as of the FY2017 annual report.
Develops a non-porcine digestive-enzyme treatment for people with pancreatic insufficiency and a medicine candidate for patients with IgA nephropathy.
10-K for FY2017, filed Mar 5, 2018Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative…View ↗
Sollpura is a novel, non-porcine PERT that contains three biotechnology-derived digestive enzymes: a lipase, a protease and an amylase.…View ↗
Our Phase 2 Development of Blisibimod for Immunoglobulin A NephropathyView ↗
A former collaboration partner, Zenyaku, reimbursed research costs as the work was done; license fees were tied to the product-development period. The collaboration ended in 2016.
10-K for FY2017, filed Mar 5, 2018During 2015, the Company had a collaboration with Zenyaku Kogyo Co., Ltd. (“Zenyaku”) which provided for various types of payments from…View ↗
The deliverables under the Zenyaku agreement had been determined to be a single unit of accounting and as such any license fees received…View ↗
For the collaborative research activities, the Company was entitled to reimbursement from Zenyaku for its internal personnel cost at a…View ↗
$245K
10-K for FY2012, filed Mar 26, 2013
$245K ↗
A former collaboration partner, Zenyaku, reimbursed research costs; the company had not generated revenue from commercial product sales.
10-K for FY2017, filed Mar 5, 2018
No. It lost $45.3M in FY2012.
10-Q for Q1 FY2018, filed May 15, 2018
−$7.7MView ↗
8-K, filed Jul 9, 2018
On July 6, 2018, the Board of Directors determined that in order to complete the expected delisting of its common stock, the Company will…View ↗
8-K, filed Jun 27, 2018
On June 27, 2018, Anthera Pharmaceuticals, Inc. (the “Company”) announced that it has withdrawn its request for a hearing to appeal the…View ↗
8-K, filed Mar 12, 2018
HAYWARD, Calif., March 12, 2018 – Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Sollpura did not meet the…View ↗
Shrank.
Revenue fell 76% in 2 years, from $1M in FY2010 to $245K in FY2012, about 51% a year.
10-K for FY2012, filed Mar 26, 2013
Competes with Abbvie, Janssen/J&J, Allergan, Chiesi, and AzurRx
10-K for FY2017, filed Mar 5, 2018Compound Stage Company Indications Notes Creon Approved Abbvie EPI, CF, CP, pancreatectomy Ÿ Porcine, enteric coated Pancreaze Approved…View ↗
Loading...
